ArticleBMC cancer2010
Altered time structure of neuro-endocrine-immune system function in lung cancer patients.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hypothalamic-Pituitary-Adrenal Axis Dysfunction in People With Cancer: A Systematic Review.Cancer medicine · 2024Pooled it
- Decoding Immuno-Competence: A Novel Analysis of Complete Blood Cell Count Data in COVID-19 Outcomes.Biomedicines · 2024Article
- Unraveling the role of the circadian clock genes in cervical squamous cell carcinoma and endocervical adenocarcinoma: A prognostic indicator for prognostic, immunotherapy response, and chemotherapy sensitivity.Journal of Cancer · 2024Article
- Improving the Accuracy of Continuous Blood Glucose Measurement Using Personalized Calibration and Machine Learning.Diagnostics (Basel, Switzerland) · 2023Article
- Circadian disruption and cancer- and treatment-related symptoms.Frontiers in oncology · 2022Review
- Prognostic Implication of Energy Metabolism-Related Gene Signatures in Lung Adenocarcinoma.Frontiers in oncology · 2022Article
- Identification of circadian clock genes as regulators of immune infiltration in Hepatocellular Carcinoma.Journal of Cancer · 2022Article
- Circadian clock: a regulator of the immunity in cancer.Cell communication and signaling : CCS · 2021Review
- Proteoglycans in the Pathogenesis of Hormone-Dependent Cancers: Mediators and Effectors.Cancers · 2020Review
- Systemic Regulation of Cancer Development by Neuro-Endocrine-Immune Signaling Network at Multiple Levels.Frontiers in cell and developmental biology · 2020Review
- The biological clock and the molecular basis of lysosomal storage diseases.JIMD reports · 2015Article
- Hormones and immunity in cancer: are thyroid hormones endocrine players in the microglia/glioma cross-talk?Frontiers in cellular neuroscience · 2015Article
- Crosstalk between the circadian clock circuitry and the immune system.Chronobiology international · 2013Review
- Circadian rhythm disruption in cancer biology.Molecular medicine (Cambridge, Mass.) · 2012Review
- Immunity's fourth dimension: approaching the circadian-immune connection.Trends in immunology · 2012Review
- Personalized therapy for metastatic melanoma: could timing be everything?Future oncology (London, England) · 2012Review
- Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls.Clinical and experimental medicine · 2012Article
- Starvation, detoxification, and multidrug resistance in cancer therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe onset and the development of neoplastic disease may be influenced by many physiological, biological and immunological factors. The nervous, endocrine and immune system might act as an integrated unit to maintain body defense against this pathological process and reciprocal influences have been evidenced among hypothalamus, pituitary, thyroid, adrenal, pineal gland and immune system. In this study we evaluated differences among healthy subjects and subjects suffering from lung cancer in the 24-hour secretory profile of melatonin, cortisol, TRH, TSH, FT4, GH, IGF-1 and IL-2 and circadian variations of lymphocyte subpopulations.
methodsIn ten healthy male volunteers (age range 45-66) and ten male patients with untreated non small cell lung cancer (age range 46-65) we measured melatonin, cortisol, TRH, TSH, FT4, GH, IGF-1 and IL-2 serum levels and percentages of lymphocyte subpopulations on blood samples collected every four hours for 24 hours. One-way ANOVA between the timepoints for each variable and each group was performed to look for a time-effect, the presence of circadian rhythmicity was evaluated, MESOR, amplitude and acrophase values, mean diurnal levels and mean nocturnal levels were compared.
resultsA clear circadian rhythm was validated in the control group for hormone serum level and for lymphocyte subsets variation. Melatonin, TRH, TSH, GH, CD3, CD4, HLA-DR, CD20 and CD25 expressing cells presented circadian rhythmicity with acrophase during the night. Cortisol, CD8, CD8(bright), CD8(dim), CD16, TcRdelta1 and deltaTcS1 presented circadian rhythmicity with acrophase in the morning/at noon. FT4, IGF-1 and IL-2 variation did not show circadian rhythmicity. In lung cancer patients cortisol, TRH, TSH and GH serum level and all the lymphocyte subsubsets variation (except for CD4) showed loss of circadian rhythmicity. MESOR of cortisol, TRH, GH, IL-2 and CD16 was increased, whereas MESOR of TSH, IGF-1, CD8, CD8(bright), TcRdelta1 and deltaTcS1 was decreased in cancer patients. The melatonin/cortisol mean nocturnal level ratio was decreased in cancer patients.
conclusionThe altered secretion and loss of circadian rhythmicity of many studied factors observed in the subjects suffering from neoplastic disease may be expression of gradual alteration of the integrated function of the neuro-immune-endocrine system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.